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1. Introduction
Regardless of the administration route, the key 
factor for the success and reliability of any formula-
tion is drug bioavailability, defined as the rate and 
extent at which the active drug is absorbed from a 
pharmaceutical form and becomes available at the 
site of drug action.1 Although metabolism and phys-
iological factors highly affect drug absorption by 
living tissues, bioavailability is strongly dependent 
on drug permeability through cell membranes and 
on drug dissolution in physiological fluids. In partic-
ular, dissolution becomes the most important factor 
in terms of bioavailability for poorly water-soluble 
– highly permeable drugs (class II drugs according 
to the Amidon classification2). This aspect is of par-
amount importance if we know that, at present, 
about 40 % of the drugs being in the development 
pipelines are poorly soluble, up to 60 % of synthe-
tized compounds are poorly soluble,3 and 70 % of 
the potential drug candidates are discarded due to 
low bioavailability related with poor solubility in 
water.4 Examples of commonly marketed drugs that 
are poorly soluble in water (less than 100 mg cm–3) 
include analgesics, cardiovasculars, hormones, anti-
virals, immune suppressants and antibiotics.5
Since it is well known that solubility increases 
with drug nanocrystal size decrease,5 this paper fo-
cuses on the theoretical relation existing between 
nanocrystal size, solubility and dissolution rate. To 
this end, a thermodynamic model relating to nano-
crystal dimensions (radius), melting temperature/
enthalpy and solubility will be presented and dis-
cussed.
2. Materials and methods
Vinpocetine (C22H26N2O2, molecular weight 
Mw = 350.45 (–)), a kind gift from Linnea SA 
( Riazzino-Locarno, CH, Switzerland), is a semisyn-
thetic derivative of the Vinca minor L. alkaloid vin-
camine6 used for the treatment of cognitive disor-
ders and related symptoms such as cerebral 
infarction, cerebral hemorrhage residual and cere-
bral arteries cirrhosis.7 This base-type drug (pKa = 
7.1)8 was chosen as a model drug because it is prac-
tically insoluble in water (1.6 mg mL–1 in pH = 7.4 
at 37 °C).9 Vinpocetine melting temperature (Tm∞ = 
149.6 °C), melting enthalpy (DHm∞ = 94600 J kg
–1) 
and DCp (difference in specific heat capacity at con-
stant pressure between the liquid ( lpC ) and the solid 
( spC ), DCp = 374 J kg
–1 °C–1) were measured by 
a differential scanning calorimeter (Mod. TA 4000, 
equipped with a measuring cell DSC 20 Mettler). 
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The calibration of the instrument was performed 
with indium. A sample, containing about 2 mg of 
vinpocetine was placed in pierced aluminum pans 
and heated at a scanning rate of 10 °C per minute 
under air atmosphere. Solid vinpocetine density 
(rs = 1268 kg m
–3) was measured by a helium pic-
nometer (Quantachrome, Boynton Beach, Florida) 
while liquid vinpocetine density (rl = 1217 kg m
–3) 
was determined as the ratio between the molecu-
lar weight Mw and the liquid vinpocetine molar 
 volume (Mv). Mv (= 287.5· 10
–6 m3 mol–1) was eval-
uated according to the group contribution ap-
proach10,11 implemented by the Breitkreutz soft-
ware.12
Determination of the solid vinpocetine – vapor 
surface tension ( svg ) was performed according to 
the following equation of state:13




cos 2 exp 1 
g
q  b g g 
g
 (1)
where qi is the contact angle of liquid “i” on solid 
vinpocetine, b is a model fitting parameter and lvig  
is the liquid i – vapor surface tension. Four liquids 
of decreasing polarity (1-water, lv1g  = 72.8 mJ m–2; 
2-ethylene glycol, lv2g  = 48 mJ m–2; 3-dimethyl 
sulfoxide, lv3g  = 44 mJ m–2; 4-diiodomethane, 
lv
4g  = 
50.8 mJ m–2)5 were considered. Eq. (1) fitting to ex-
perimental cos(qi) yielded to 
sv
g  = 38.4 mJ m–2 and 
b = 1.5· 10–4 (m4 mJ–2). Contact angles (water, q1 = 
82°; ethylene glycol, q2 = 61°; dimethyl sulfoxide, 
q3 = 37°; diiodomethane, q4 = 33°) were measured 
by the tensiometer G10, Kruss, GmbH, Hamburg, 
D. Determination of the liquid vinpocetine – vapor 
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 (2)
The solid– liquid vinpocetine ( slg ) surface ten-
sion was evaluated according to the Young equation 
for pure substances (q = 0):15
 sl sv lv 27.2 (mJ m )  g  g g   (3)
The solid vinpocetine – water ( sl1g ) surface ten-
sion was evaluated according to the Young equa-
tion15 (q1 = 82°):
  sl sv lv 21 1 1cos 27.8 (mJ m )g  g g q   (4)
The Tolman length d16 for vinpocetine (d is 
equal to 1/3 of vinpocetine molecule diameter17) 
was evaluated resorting to the knowledge of liquid 
vinpocetine molar volume Mv and assuming a 











where NA is the Avogadro number.
Finally, the Crystallographic Information File 
(CIF) of vinpocetine was extracted from the Interna-
tional Union of Crystallography database.18 Vinpo-
cetine shows a monoclinic crystal system with the 
following unit cell parameters: a = 0.8907 nm, 
aa = 90°, b = 0.953 nm, bb = 106.57°, c = 0.11286 nm, 
gc = 90°, unit cell volume 0.9182 nm
 3. Vinpocetine 
unit cell corresponds to a sphere of radius approxi-
mately equal to 0.5 nm.
3. Drug dissolution
The dissolution of a solid in a solvent is a rath-
er complex process determined by a multiplicity of 
physicochemical properties of the solute and sol-
vent.5 Typically, for a fixed solid-solvent couple, 
solid solubility, liquid environment fluido-dynamic 
conditions, dissolution surface and solid wettability 
are the key factors affecting the dissolution kinet-
ics.5,19 In addition, for what concerns solid solubili-
ty, temperature and pH play predominant roles 
whilst pressure is generally less important. Howev-
er, pH becomes the key parameter for the crowded 
class of small organic drugs behaving as weak acids 
or bases.20 Indeed, as the solubility of the dissociat-
ed form can be much higher than that of the un-dis-
sociated form, the relation between environmental 
pH and drug pKa being fundamental. For example, 
nimesulide (pKa = 6.5),21 a weak acid nonsteroidal 
anti-inflammatory drug, increases its solubility by 
about one order of magnitude, from pH = 1.2 (37 °C: 
solubility ~ 10 mg mL–1; nimesulide is un-dissociat-
ed) to pH = 7.5 (37 °C: ~ 100 mg mL–1; nimesulide 
is dissociated).22 When temperature and pH are 
fixed, it is well known that solubility also depends 
on the solid melting temperature and enthalpy23 
that, in turn, depend on solid crystals dimensions, as 
discussed in the next sections 4 and 5. In particular, 
the smaller the crystals, the lower their melting tem-
perature/enthalpy and, consequently, the higher 
their solubility. Accordingly, in order to discern the 
effect of equilibrium (solid solubility) and kinetics 
(fluido-dynamic conditions, wettability, and disso-
lution surface) factors, let us focus on the dissolu-
tion process of a solid phase subdivided in many 
spherical particles, having the same diameter. In ad-
dition, we assume that particles do not aggregate 
during dissolution and that the initial amount of the 
solid phase (M0) is so high that at equilibrium (i.e. 
when solid concentration reaches solubility in the 
liquid phase) the variation of the solid particles ra-
dius is negligible. Accordingly, for the generic solid 
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particle, the physical situation we are referring to is 
depicted in Fig. 1. Dissolution can be considered as 
a consecutive process driven by four energy chang-
es DEi: 1) Contact of the solvent with the solid sur-
face (wetting), which implies the production of a 
solid–liquid interface starting from solid–vapor one 
(DE1 = DEw) 2) Breakdown of molecular bonds of 
the solid (fusion; (DE2 = DEf)) 3) Solid molecules 
transfer to the solid–liquid interface (solvation; 
(DE3 = DEs)) 4) Movement of the solvated mole-
cules from the interfacial region into the bulk solu-
tion (diffusion; (DE4 = DEd)). The sum of the ener-
gies relative to the four mentioned steps represents 
the total energy required for solid dissolution. Obvi-
ously, the higher the dissolution energy required, 
the lower the dissolution kinetics. In order to con-
nect these four energy contributes to the equilibri-
um and the kinetics parameters ruling solid dissolu-
tion, we need a mathematical model linking the 
time evolution of the solid concentration profile 
(C(r)) in the stagnant layer with the solid molecules 
concentration in the bulk liquid (Cb). Obviously, 
C(r) is given by the solution of the so-called second 
Fick’s law:




   
    
   
 (6)
where t is time, r is the radial position and D is the 
solid molecules diffusion coefficient in the stagnant 
layer (D can be considered constant in the stagnant 
layer thickness5). Assuming that a pseudo-stationary 
condition can be rapidly achieved in the stagnant 
layer (this hypothesis is supported by the numerical 
solution of eq. (6) assuming usual values for D 
(~ 10–10 m2 s–1)5 and stagnant layer thickness (hSL) 









The solution of eq. (7), subjected to the follow-
ing initial boundary conditions:
initial:
 C(r) = 0  Rc < r < Rs (8)
boundary:
 C(Rs) = Cb (9)











leads to the solid molecule concentration profile 
C(r) in the stagnant layer surrounding the solid par-
ticles (see details in Appendix):
  
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 (11)
where Rc is the particle radius (supposed time inde-
pendent; see Fig. 1), Rs is the stagnant layer radius 
(supposed time independent; see Fig. 1), 1/km is the 
solid-liquid interface mass transfer resistance while 
kd (= D/hSL; hSL = Rs – Rc) is the so-called dissolu-
tion constant.5 While eq. (8) simply states that the 
stagnant layer is initially drug empty, eq. (9) affirms 
that, in Rs, the solid molecules concentration equals 
the bulk one. Finally, eq. (10) affirms that solid 
molecules flux at the solid–liquid interface (Rc) de-
pends on both km and the difference between drug 
solubility (Cs) and actual local drug concentration 
(C(Rc)). An inspection of eq. (11) reveals that C(Rc) 
develops from a fraction of Cs (for t = 0, Cb = 0 and 
C(Rc) = Cs (km/kd)Rc/(Rs + (km/kd)Rc)) to Cs for a very 
long time. This is due to the mass transfer resistance 
(1/km) that accounts also for solid surface wettabili-
ty problems. Indeed, when this resistance is zero, 
C(Rc) is always equal to Cs.
In order to complete the dissolution model, it is 
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F i g .  1  – Solid drug dissolution in a solvent liquid phase im-
plies overcoming four energy barriers represented by solid wet-
ting (DEw), breakdown (fusion) of solid molecular bonds (DEf), 
drug molecules solvation (DEs) and drug molecules diffusion 
through the solvent stagnant layer to reach the bulk solvent 
(DEd). These energies affect, in different manners, the mass 
transfer coefficient (km) at the solid/liquid interface, the disso-
lution constant kd and the drug solubility Cs(DEf). It is import-
ant to stress that, due to possible solid surface wetting prob-
lems, the solid molecule concentration at the solid/liquid 
interface (C(Rc)) can be lower than Cs, as shown by eq. (11).
250 D. HASA et al., Drug Nanocrystals: Theoretical Background of Solubility Increase and…, Chem. Biochem. Eng. Q., 28 (3) 247–258 (2014)
Eq. (12) imposes that the increase rate of the 
solid molecules concentration in the bulk liquid 
(volume V) depends on the mass flux in Rs and on 
the release surface ( 2p s4N Rp ), being Np the number 
of particles considered and rs their density. Eq. (12) 
solution (see details in Appendix) is:











    
  r     
 (13)
Assuming, for the sake of simplicity, that the 
ratio Rc/Rs does not sensibly depend on Rc, eq. (13) 
indicates that a reduction of particles radius (Rc), 
being constant V and M0, implies the improvement 
of the dissolution kinetics as the dissolution surface 
increases proportionally to M0/(Rcrs). However, it 
will be demonstrated in the following sections 4 
and 5 that Rc reduction also implies a dissolution 
kinetics increase due to Cs increase. It is worth not-
ing that this last effect becomes important only for 
very small particles (Rc < 50 nm). On the basis of 
eq. (13) and Fig. 1, it is possible to argue that km and, 
thus, 1/km, depend on DEw, DEf and DEs (km → ∞ 
when crystal breakdown is very fast, no wettability 
problems occur (solid/liquid contact angle less than 
≈ 30°) and solvation is very rapid). At the same 
time, kd depends on DEd (the lower this energy, the 
higher the solid molecules mobility (D) in the stag-
nant layer), while Cs depends only on DEf (at fixed 
temperature and pH) as discussed in sections 4 
and 5.
4. Nanocrystal solubility dependence 
   on melting enthalpy/temperature
The peculiar behavior of very small crystals is 
explained by the different characteristics of the sur-
face and bulk phases. Indeed, due to their less con-
fined arrangement (fewer inter-atomic bonds),24 sur-
face atoms/molecules are characterized by a higher 
energy content with respect to bulk atoms/mole-
cules. Consequently, lattice breakdown on crystal 
surface would require less energy and would be fa-
vored over bulk lattice breakdown. This theoretical 
interpretation, supported by experimental data and 
molecular dynamics simulations,25 clearly reveals 
the importance of surfaces as stand-alone phases. 
Obviously, the effect of surfaces becomes relevant 
(i.e., appreciable at the macroscopic level) only 
when the number of surface atoms/molecules is not 
negligible compared to that of the bulk atoms/mol-
ecules, which happens when the crystal surface/vol-
ume ratio is very high, i.e. when crystal size falls in 
the nanometer range.26 The immediate consequence 
of the different behavior of surface atoms/molecules 
is that nanocrystals are characterized by a decreas-
ing melting temperature/enthalpy as the nanocrystal 
radius (Rc) decreases. The thermodynamic equilibri-
um condition between a liquid phase (solvent) and a 
solid phase (drug) yields to the Cs dependence on 
solid crystals radius Rc, provided that the solid sur-
face properties are properly accounted for.26,27 As-
suming that only the drug partitions between the 
two phases (this means that the solvent does not go 
inside the drug), the equilibrium condition requires 
that the solid drug fugacity ( sd̂f ) and liquid phase 
drug fugacity ( ld̂f ) are equal:
 l l s sd d d d d dˆ ˆf X f f f g    (14)
where gd and Xd are, respectively, the drug activity 
coefficient and solubility (molar fraction) in the sol-
vent, ldf  is the drug fugacity in the reference state, 
while sdf  is the drug fugacity in the solid state. 












If we assume that ldf  is the fugacity of the pure 
drug in the state of undercooled liquid at system 
temperature (T) and pressure (P), the ratio s ld df f  
can be evaluated as the variation of the molar Gibbs 
free energy (Dgda) between the state of undercooled 
liquid drug (state d) and solid (nanocrystalline) drug 
(state a) (see Fig. 2):
F i g .  2  – Thermodynamic cycle used to estimate the ratio 
s l
d df f  (solid drug fugacity in the reference state “a” / drug 
fugacity in the state of undercooled liquid (state “d”)). This 
ratio is linked to the Gibbs free energy variation between states 
“a” and “d” (Dgda), by the relation:  l sda d dlng RT f fD  . g, 
s and h indicate, respectively, the molar Gibbs energy, entropy 
and enthalpy. Tm is the nanocrystals melting enthalpy. Adapted 
from ref. 26.
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 (16)
where R is the universal gas constant, while the en-
thalpy (Dhba, Dhcb, Dhdc) and entropy (Dsba, Dscb, 
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 [as dP = 0] (19)
where Tm is the nanocrystal melting temperature, 
s
pc  
and lpc  are, respectively, the solid (drug) and liquid 
(drug) molar specific heat at constant pressure while 
Dgm, Dhm and Dsm are, respectively, the molar nano-
crystals melting Gibbs free energy, enthalpy and en-
tropy. Upon rearrangement of eqs. (16)–(19), drug 
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 (20)
where Dcp = 
l
pc  – 
s
pc .
Finally, molar solubility Xd can be expressed as 
the mass/volume solubility Cs:








where Md and Ms are drug and solvent molecular 
weight, respectively, while rsol is solvent density. In 
order to understand the effect of nanocrystal radius 
Rc decrease on Xd or Cs, the dependence of Dhm and 
Tm on Rc has to be necessarily expressed.
5. Melting enthalpy/temperature 
   dependence on nanocrystal radius
The physics of nanocrystals melting can be de-
scribed by the three different mechanisms28 reported 
in Fig. 3. According to the Homogeneous Melting 
approach (HM), the solid (spherical) crystal is in 
equilibrium with a liquid (spherical) phase having 
the same mass and both are embedded in the vapor 
phase. The Liquid Skin Melting theory (LSM) as-
sumes the formation of a thin liquid layer over the 
solid core. The thickness of the liquid layer remains 
constant until the solid core completely melts. On 
the contrary, in the Liquid Nucleation and Growth 
approach (LNG), the liquid layer thickness increas-
es as it approaches the melting temperature. Ac-
cordingly, the solid core melting takes place when 
the liquid layer thickness is no longer negligible in 
comparison to the solid core radius.
In a previously published work,26 we theoreti-
cally demonstrated the connection existing among 
melting temperature/enthalpy and nanocrystals radi-
us (Rc). In particular, efforts were made to properly 
express the infinitesimal, reversible, variation of the 
internal energy E (dE) referred to the closed system 
composed of solid drug, liquid drug and vapor drug. 
In that demonstration, the connection among dE 
and the LSM, LNG, HM frames (i.e. the relations 
existing among the solid, liquid and vapor phases; 
see Fig. 3) was introduced only in a late stage of the 
demonstration. In this work, on the contrary, we 
would like to follow a more physically-oriented 
strategy aimed to immediately consider the rela-
tions existing among the three phases according to 
the LSM, LNG, HM mechanisms. We believe that 
the coincidence of the final results, coming from the 
two approaches, strengthens the whole theoretical 
approach.
LSM and LNG mechanisms
The starting point is the definition of dE for the 
closed system (no matter or energy exchanges with 
Homogeneous Melting Liquid Skin Melting Liquid Nucleation and Growth
F i g .  3  – Melting mechanisms: Homogeneous Melting, Liquid 
Skin Melting, Liquid Nucleation and Growth. Rv indicates the 
radius of the vapor phase while Rsv, Rlv and Rsl are, respectively, 
the solid-vapor, liquid-vapor and solid-liquid interface radii. 
Adapted from ref. 26.
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the surroundings, i.e. system volume, entropy and 
moles number are constant) composed of one com-
ponent and 3 phases (s solid, l liquid, v vapor)15 
whose spatial organization is that of the LNG and 
LSM melting mechanisms (see Fig. 3):
 s l v sl lvd d d d d dE E E E E E      (22)
where Es, El, Ev, Esl, Elv represent the solid, liquid, 
vapor, solid/liquid and liquid/vapor phase internal 
energy, respectively. Assuming that a) the contribu-
tion of the first and the second curvatures to system 
internal energy, E, is negligible (this is strictly true 
for planes and spheres), and that b) thermal and 
chemical equilibrium is attained among the bulk 
and surface phases (same temperature and chemical 
potential in all bulk and surface phases), eq. (22) 
becomes:
v v s s l l sl sl lv lvd d d d d dE P V P V P V A A   g g  (23)
where P is pressure, V is volume, A is interfacial 
area, g is interfacial tension while superscripts sl 
and lv are solid-liquid and liquid-vapor, respec-
tively. In the light of the closed system hypothesis 
(dVl = – dVv – dVs), we have:
 
   v l v s s l
sl sl lv lv
d d d
d d
E V P P V P P
A A
    
g g
 (24)
The system equilibrium condition (dE = 0) im-
plies:
  l v lv lv vd dP P A V  g
 v l lv lv vd d d dP P A V g  (25)
  s l sl sl sd dP P A V  g
 s l sl sl sd d d dP P A V g  (26)
These relations can be inserted in the Gibbs-
Duhem equation referring to the solid, liquid and 
vapor phases:
   s s1d d d 0
ss T v P m    solid (27)
   l l1d d d 0
ls T v P m    liquid (28)
   v v1d d d 0
vs T v P m    vapor (29)
where ss, sl and sv indicate the molar entropy of the 
solid, liquid and vapor phases, respectively, m1 is 
the chemical potential (equal for all three phases in 
hypothesis (b)), vs, vl and vv are, respectively, the 
molar volume of the solid, liquid and vapor phases, 
and T is temperature. Subtracting eq. (28) from eq. 
(27) and eq. (29) from eq. (28) leads to:
  s l s ld d d 0s ls s T v P v P     (30)
  l v l vd d d 0l vs s T v P v P     (31)
Inserting in eqs. (30)–(31) the expressions of 
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Equating eqs. (32) to (33), we have:
 
 
s l l v s
sl sl s




d d d d
d d d
s s s s v
T A V





   g 




Remembering that vv >> vl ≈ vs, it follows 
l v s l
l v s l
s s s s




 and vv/(vl – vv) ≈ –1. Thus, eq. 
(34) becomes:
 
   
 
s l lv lv v
m
s sl sl s
d d d d
d d d
s T v v A V
v A V
D   g 
 g
 (35)
where Dsm is the molar melting entropy (s
l – ss). In 
order to make eq. (35) operative, it is necessary to 
evaluate the two differential terms involving areas, 
volumes and surface tensions. In particular, for 
spherical crystals, we have:
 sl 2sl4A R p   
sl
sl sld 8A R dR p
  s 3sl4 3V R p   
s 2
sl sl4 ddV R R p  (36)
 lv 2lv4A R p   
lv
lv lvd 8A R dR p
  v 3 3v sl4 3V R R p   v 2lv lv4 ddV R R p  (37)
 sl s sld d 2A V R  
lv v
lvd d 2A V R  (38)
where Rsl and Rlv represent the curvature radius 
proper to the solid-liquid and liquid-vapor interface, 
respectively (see Fig. 3). In addition, the surface 
tension g dependence on the interface curvature ra-
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where g∞ and g are, respectively, the surface tension 
competing to a flat surface (infinite curvature radi-
us) and a surface of curvature radius Rc, while d is 
the Tolman length whose order of magnitude should 
correspond to the effective molecular diameter md 
and it is usually assumed17 to be md/3. On the basis 





d 2 d 2 d
2 2
h
T v v v
T R R
 
   D g g
     
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where Dhm is the molar melting enthalpy. The inte-
gration of eq. (40) between the melting temperature 
of the infinitely large crystal (Tm∞, Rlv →∞, Rsl → ∞) 
and the melting temperature (Tm) of the crystal of 
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where rl and rs are, respectively the density of the 
liquid and solid phases. Establishing a relation be-
tween Rlv and Rsl is now essential. To this end, a 
generalized version of the strategy adopted by 
Coceani27 can be undertaken. This approach relies 
upon the fact that, very often, drug crystals’ melting 
occurs in the presence of a drug amorphous solid 
that becomes liquid before the melting temperature. 
Indeed, as the glass transition temperature of the 
amorphous drug is lower than the crystals’ melting 
temperature (whatever Rsl), the amorphous drug will 
be liquid before the nanocrystals melting. Thus, at 
melting point, the nanocrystals mass fraction, Xnc, 
can be evaluated as:
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Consequently, we have:










 Rc = Rsl (44)
It is easy to verify that the LSM condition occurs 
for Xnc ≈ 1 (the amorphous, liquid phase is virtually 
absent; Rlv ≈ Rc), while LNG condition takes place for 
Xnc ≈ 0 (nanocrystal melting occurs in a virtually in-
finite liquid phase, Rlv ≈ ∞). For 0 < Xnc < 1, we can 
account for what usually happens during the melting 
of organic drug crystals embedded in a polymeric 
stabilizing carrier.27 When Xnc is unknown, its deter-
mination implies an iterative procedure based on the 
knowledge of the differential scanning calorimetry 
trace referring to the melting of the amorphous/crys-
tal drug.26,27
It is interesting to note that the results of the 
approach presented in this paper lead to what was 
previously demonstrated following a different 
path.26
HM mechanism
In the case of the homogeneous melting, the 
expression of the infinitesimal, reversible, variation 
of the internal energy E reads:
v v s s l l sv sv lv lvd d d d d dE P V P V P V A A   g g  (45)
It is worth noting that eq. (45) differs from eq. 
(23) in that the term gsldAsl is substituted by the term 
gsvdAsv. Indeed, in the HM case, the solid/liquid in-
terface no longer exists (see Fig. 3), while it is re-
placed by the solid/vapor interface. Starting from 
eq. (45) and following a procedure analogue to that 
shown for the LSM and LNG approaches, we ob-
tain:
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Remembering that in the HM case the solid and 
liquid phases are characterized by the same mass, 
the relation between Rlv and Rsl (= Rc) is:
    3 3sl s lv l4 3 4 3R Rp r  p r  ==>
  1 3lv c s lR R r r  Rc = Rsl (47)
6. Results
In order to integrate eq. (42) and (46), it is nec-
essary to know the DHm dependence on Rc and Tm. 
Therefore, the thermodynamic relation used by 
Zhang and co-workers,29 holding regardless of 
nanocrystal nature (organic or inorganic) and char-
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where DHm∞ is the specific melting enthalpy (J Kg
–1) 
referred to the infinite radius drug crystal, DCp 
(J kg–1 K–1) is the difference between the liquid and 
solid drug specific heat capacity at constant pres-
sure. As DCp is almost temperature invariant, the 
integral in eq. (48) can be approximated by DCp 
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(Tm∞ – Tm). Figs. 4A and 4B indicate, respectively, 
the reduction of vinpocetine melting temperature 
(Tm) and melting enthalpy (DHm) with crystal radius 
(Rc) according to eq. (42) in the case of liquid skin 
melting (Xnc = 1), liquid nucleation and growth 
(Xnc ≈ 0) mechanisms. It can be seen that, for both 
mechanisms, an appreciable effect of Rc reduction 
takes place for Rc < 50 nm, while Tm and DHm un-
dergo a considerable reduction for Rc < 10 nm. On 
the contrary, the effect of Xnc seems limited, and this 
is mainly due to the fact that vinpocetine density 
does not significantly change from the solid to the 
liquid state (see eq. (42)). Interestingly, we found 
similar results using other poorly water soluble 
small organic drugs, i.e., nifedipine, griseofulvin26 
and nimesulide.27 In the case of griseofulvin and 
nifedipine, model predictions were substantially 
confirmed by means of the X rays evaluation of 
nanocrystal dimensions.26
Fig. 5A shows, according to eq. (20), the in-
crease of vinpocetine nanocrystal solubility (Cs) 
with Rc reduction for two different Xnc values (1, 
LNG; ≈ 0, LNG). Also in this case, an appreciable 
effect takes place for Rc < 50 nm and the effect ex-
erted by Xnc is not so relevant. For the smallest 
nanocrystals, Cs is about 3 times that of the infinite-
ly large vinpocetine crystals (Cs∞).
While model verification can be conducted, in 
its thermal part, e.g. with X ray analysis,26 the proof 
of the solubility enhancement is much more diffi-
cult due to the experimental difficulty of measuring 
the solubility of drug nanocrystals and amorphous 
drugs.30–33 Some useful considerations can be drawn 
by making a comparison between our model and 













F i g .  4  – A) Reduction of melting temperature Tm with crystal 
radius Rc in the case of Vinpocetine. B) Reduction of the melt-
ing enthalpy DHm with crystal radius Rc in the case of Vinpoce-
tine. Xnc is the nanocrystal mass fraction. Prediction according 
to eq. (42).
F i g .  5  – A) Increase of vinpocetine solubility with nanocrys-
tals radius Rc decrease according to eq. (20) and the Tm and 
DHm trend shown in Fig. 4A, B. Cs is the solubility of the vinpo-
cetine nanocrystal of radius Rc, while Cs∞ is the solubility of an 
infinitely large vinpocetine crystal. Xnc is the nanocrystal mass 
fraction (simulations referred to 37 °C). B) Increase of vinpo-
cetine solubility according to our approach (eq. (20); solid lines) 
and the Ostwald-Freundlich approach (eq. (49); dashed line) 
(simulations referred to 37 °C).
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Assuming T = 37 °C, Mvs = (= 276 ·  10
–6 m3 mol–1) 
and the sl1g  value evaluated in section 2 (Materials 
and Methods), eq. (49) prediction is shown in Fig. 
5B (dashed line) jointly with the predictions of our 
approach (solid thin and thick lines). It can be no-
ticed that for small crystals eq. (49) leads to an un-
reasonable solubility increase keeping in mind that, 
in general, the solubility increase of amorphous drugs 
(not too dissimilar from vinpocetine) have been the-
oretically estimated in the range (7 – 100).35 On the 
contrary, the prediction of our model seems more 
reasonable. Nevertheless, we recognize that the diffi-
culty connected to the experimental measurement of 
nanocrystals solubility leaves this question still open.
7. Conclusions
In this paper, we demonstrated the theoretical 
correctness of our previous approach aimed at the 
evaluation of melting temperature/enthalpy depres-
sion with decreasing nanocrystals radius. Indeed, by 
means of a more physically oriented approach, we 
confirmed the theoretical results of our previous 
work. In addition, considering these results in the 
frame of drug dissolution, we proved that nanocrys-
tals can play a very important role in the pharma-
ceutical field as they can enhance the bioavailability 
of poorly soluble – highly permeable drugs. Indeed, 
the concomitant decrease in melting temperature 
and enthalpy has a double beneficial effect on 
drug dissolution and, ultimately, on drug bioavail-
ability. On the one hand, melting enthalpy reduction 
(DHm = DEf at constant temperature and pressure, 
see Fig. 1) improves the dissolution process by re-
ducing one of the most important energy-related 
steps involved in drug dissolution (i.e. breakdown 
of the crystalline network (step 2 in Fig. 1), con-
nected to the mass transfer resistance 1/km). On the 
other hand, it increases drug solubility (see eq. (20) 
and Fig. 5A). As a result, the dissolution rate can be 
increased considerably.
Interestingly, despite the mathematical (not 
physical) complexity connected to the theoretical 
study of the relation existing between nanocrystals 
size and solubility, the preparation of drug nano-
crystals is no longer problematic since many reli-
able technologies are available nowadays.36,37 This 
is of particular interest if we know that, until now, 
about 70 % of the potential drug candidates are dis-
carded due to low bioavailability related with poor 
solubility in water.4 Obviously, the problem of bio-
availability enhancement of poorly soluble drugs 
also requires the estimation of drug solubility in the 
drug amorphous state that can be considered as a 
nanocrystal of vanishing dimensions. In this re-
spect, the work of Bogner and co-workers35 is a 
very interesting theoretical contribution.
APPENDIX
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The integration constants A1 and A2 can be 
evaluated by means of the boundary conditions ex-
pressed by eqs. (9) and (10):
 C(Rs) = Cb (9)











From eqs. (9) and (10), we have:
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The solution of the linear system represented 
by eqs. (A3) and (A4) leads to the determination of 
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Inserting these expressions for A1 and A2 into 
eq. (A2), leads to eq. (11).
Starting from eq. (11), it is possible to solve eq. 
(12) since we now have an analytical expression for 
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Remembering that the number of particles is 
given by Np = M0/((4/3)prRc
3) and that kd = D/hSL, 
eq. (A7) can be rearranged to give:
 
   
b 0 m
s b









This first order differential equation can be 
solved by means of standard techniques to give eq. 
(13).
L i s t  o f  s y m b o l s
a – vinpocetine unit cell side, m
Alv – liquid drug – vapor drug interface area, m2
Asl – solid drug – liquid drug interface area, m2
Asv – solid drug – vapor drug interface area, m2
b – vinpocetine unit cell side, m
c – vinpocetine unit cell side, m
C(r) – drug concentration profile in the stagnant layer, 
kg m–3
Cb – drug concentration in the bulk liquid, kg m
–3
Cs – nanocrystals drug solubility in the bulk liquid, 
kg m–3
Cs∞ – infinitely wide crystals drug solubility in the bulk 
liquid, kg m–3
l
pC  – liquid drug specific heat capacity at constant 
pressure, J kg–1 °C–1
l
pc  – molar liquid drug heat capacity at constant pres-
sure, J mol–1 °C–1
s
pC  – solid drug specific heat capacity at constant pres-
sure, J kg–1 °C–1
s
pc  – molar solid drug heat capacity at constant pres-
sure, J mol–1 °C–1
D – drug diffusion coefficient in the liquid stagnant 
layer, m2 s–1
E – system internal energy, J
Es – solid phase internal energy, J
El – liquid phase internal energy, J
Ev – vapor phase internal energy, J
Esl – solid/liquid phase internal energy, J
Elv – liquid/vapor phase internal energy, J
s
d̂f  – drug fugacity in the solid state, Pa
s
df  – pure solid drug fugacity, Pa
l
d̂f  – drug fugacity in the liquid state, Pa
l
df  – drug fugacity in the reference state, Pa
kd – dissolution constant, m s
–1
hSL – stagnant layer thickness, m
km – solid drug-liquid mass transfer coefficient, m s
–1
Md – drug molecular weight, –
md – drug molecular diameter, m
Mv – liquid vinpocetine molar volume, m
3 mol–1
Mvs – solid vinpocetine molar volume, m
3 mol–1
Ms – solvent molecular weight, –
Mw – drug molecular weight, –
M0 – initial solid drug amount considered in dissolu-
tion, kg
NA – Avogadro number, –
Np – numbers of solid spherical crystals involved in 
the dissolution process, –
P – pressure, Pa
Pl – liquid phase pressure, Pa
Ps – solid phase pressure, Pa
Pv – vapor phase pressure, Pa
Ps – Parachor, J
0.25 m2.5/mol–1
r – radial position, m
R – universal gas constant, J mol–1 K–1
Rc – crystal radius, m
Rs – stagnant layer radius, m
Rlv, Rlv – liquid-vapor interface radius, m
Rsl, Rsl – solid-liquid interface radius, m
Rsv, Rsv – solid-vapor interface radius, m
Rv – vapor phase radius, m
sl – molar liquid drug entropy, J mol–1 K–1
ss – molar solid drug entropy, J mol–1 K–1
sv – molar vapor drug entropy, J mol–1 K–1
t – time, s
T – temperature, K
Tm∞ – melting temperature of an infinitely wide drug 
crystal, K
V – bulk liquid volume, m3
Vl – liquid phase volume, m3
Vs – solid phase volume, m3
Vv – vapor phase volume, m3
Xd – drug molar fraction solubility, –
Xnc – nanocrystal mass fraction, -
G r e e k  l e t t e r s
a – eq. (12) parameter, s–1
aa – angle between directions a and b, degrees
b – model fitting parameter (eq. (1))
bb – angle between directions a and c, degrees
d – Tolman length, m
DCp – difference between the liquid and the solid 
drug specific heat capacity at constant pressure, 
J kg–1 °C–1
DE1 = DEw – energy variation related to solid drug wet-
ting, J
DE2 = DEf – energy variation related to the breakdown 
of molecular bonds of the solid, J
DE3 = DEs – energy variation related solid molecules 
solvation, J
DE4 = DEd – energy variation related to the movement 
of the solvated molecules from the interfacial re-
gion (solid drug-liquid) into the bulk liquid solu-
tion, J
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Dgda – molar Gibbs energy variation from state “d” (un-
der-cooled liquid drug at T and P) and state “a” 
(drug nanocrystals at T and P), J mol–1
Dgm – melting molar Gibb energy, J mol
–1
Dhda – molar enthalpy variation between state “d” (un-
der-cooled liquid drug at T and P) and state “a” 
(drug nanocrystals at T and P), J mol–1
Dhba – molar enthalpy variation between state “b” (drug 
nanocrystals at Tm and P) and state “a” (drug 
nanocrystals at T and P), J mol–1
Dhcb – molar enthalpy variation between state “c” (liq-
uid drug at Tm and P) and state “b” (drug nano-
crystals at Tm and P), J mol
–1
Dhdc – molar enthalpy variation from state “d” (un-
der-cooled liquid drug at T and P) to state “c” 
(liquid drug at Tm and P), J mol
–1
Dhm – molar melting enthalpy of nanocrystals, J mol
–1
DHm∞ – specific melting enthalpy of infinitely wide 
crystals, J kg–1
DHm – specific melting enthalpy of nanocrystals, J kg
–1
Dsm – nanocrystals melting molar entropy, J mol
–1
Dsda – molar entropy variation between state “d” (un-
der-cooled liquid drug at T and P) and state “a” 
(drug nanocrystals at T and P), J mol–1
Dsba – molar entropy variation between state “b” (drug 
nanocrystals at Tm and P) and state “a” (drug 
nanocrystals at T and P), J mol–1
Dscb – molar entropy variation between state “c” (liquid 
drug at Tm and P) and state “b” (drug nanocrys-
tals at Tm and P), J mol
–1
Dsdc – molar entropy variation from state “d” (un-
der-cooled liquid drug at T and P) to state “c” 
(liquid drug at Tm and P), J mol
–1
gc – angle between directions b and c, degrees
gd – drug activity coefficient, -
lv
ig  – liquid “i” – vapor surface tension (flat surface), 
J m–2
lvg  – liquid drug – vapor drug surface tension, J m–2
sl
ig  – solid drug – liquid “i” surface tension (flat sur-
face), J m–2
slg  – solid drug – liquid drug surface tension, J m–2
lv
g  – liquid vinpocetine – vapor surface tension (flat 
surface), J m–2
svg  – solid drug – vapor drug surface tension, J m–2
sv
g  – solid drug – vapor surface tension (flat surface), 
J m–2
sl
g  – solid drug – liquid drug surface tension (flat sur-
face), J m–2
m1 – chemical potential of species “1”, J mol
–1
nl – liquid drug molar volume, m3 mol–1
ns – solid drug molar volume, m3 mol–1
nv – vapor drug molar volume, m3 mol–1
rl – liquid drug density, kg m
–3
rs – solid drug density, kg m
–3
rsol – solvent density, kg m
–3
qi – contact angle of liquid “i” on solid drug, degrees
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